A single center open-label uncontrolled study to investigate tumour response and vascularization changes in neoadjuvant therapy with BAY 43-9006 single agent therapy in patients with operable renal cell cancer.

1. Patients > 18 years;
2. ECOG = 1(2);
3. Candidates for a radical or partial nephrectomy who are fit for surgery;
4. At least one uni-dimensional measurable lesion, measured by CT-scan;
5. Adequate bone marrow function;
6. Adequate liver function;
7. Adequate renal function;
8. Adequate coagulation;
9. Men and women must have adequate barrier birth control before and during and for 1 week after the trial.
10.Signed informed consent

1. History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY43- 9006;
2. History of cardiac disease congestive heart failure, cardiac arrhythmias requiring anti-arrhythmic therapy or uncontrolled hypertension;
3. History of chronic hepatitis B or C and HIV infection;
4. Patients with seizure disorders (requiring medication);
5. Patients with evidence or history of bleeding diathesis;
6. Other investigational drug therapy within 30 days;
7. Women of childbearing potential with a positive pregnancy test within 7 days before start treatment;
8. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study;
9. Unable to swallow oral medication;
10. Tumour/ disease specific criteria: chronic diarrhoea, bowel obstruction, degree of malnutrition, malabsorption;
11. Major surgery within 4 weeks before screening.